JAT follows up lucrative contract with new product launch
JAT Energy’s (ASX:JAT) 51% owned subsidiary, Golden Koala Group Pty Ltd, has developed a new OPO formula for milk products for the Australian and overseas markets.
The company has an established presence in handling Chinese-Australia cross-border fast moving consumer goods (FMCG) products.
The formula will be sold in a new range of products packaged with English language labels.
This development comes on the back of another distribution deal which was sealed only a week ago with Cyclone e-commerce.
Large addressable market
Under last week’s lucrative agreement with Cyclone, the group will be purchasing over $7.5 million in product from JAT over the next 12 months.
While the company hasn’t quantified the potential dollar value of its new OPO formula, given the large addressable market it would appear to be considerable.
Although any dollar amount is speculative at this stage4 and investors should seek professional financial advice if considering this stock for their portfolio.
The formula will be sold in a new range of products packaged with English language.
Premium and high calcium products pitched at infants to toddlers
One of the brands is Golden Koala Premium Infant Formula, a product for newborns to 6 months with a ‘premium follow-on formula’ for 6 to 12 months.
The company has also released a premium toddler milk drink pitched at the 1 to 3-year-old group which will be sold through the network of cross-border distributors that JAT has been developing in China and other countries over recent months.
High calcium Golden Koala full cream instant milk powder will be sold through cross-border distributors and in addition, wholesaled to domestic distributors for sale in Chinese shops and supermarkets.
Golden Koala has placed an initial order of one container of each of these products with its contract manufacturer in Australia.
Another step in CFDA approval process for China
JAT also informed the market that the Chinese label formulation for Golden Koala Premium Infant products has now been finalised.
This is a key milestone in the CFDA approval process for domestic Chinese distribution, as samples can now be prepared for laboratory testing.
Finalisation of the Chinese label formulation is a major precursor to the CFDA application being processed.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of Maven Capital Pty Ltd (AFSL No. 418504). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.